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The endocannabinoid system plays a key role in regulating a variety of physiological
processes such as appetite control and energy balance, pain perception, and immune
responses. Recent studies have implicated the endocannabinoid system in the regulation
of bone cell activity and bone remodeling.These studies showed that endogenous cannabi-
noid ligands, cannabinoid receptors, and the enzymes responsible for ligand synthesis and
breakdown all play important roles in bone mass and in the regulation of bone disease.
These ﬁndings suggest that the endocannabinoid pathway could be of value as a therapeu-
tic target for the prevention and treatment of bone diseases. Here, we review the role of
the skeletal endocannabinoid system in the regulation of bone remodeling in health and
disease.
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INTRODUCTION
The endogenous cannabinoid (endocannabinoid) system is a com-
plex network of receptors, a variety of ligands, and a series
of enzymes that are responsible for ligand synthesis and break-
down. Endocannabinoids and their receptors are involved in the
regulation of numerous physiological processes including neuro-
transmission, pain perception, learning, memory, cardiovascular
homeostasis, appetite, motor function, and the immune response
(reviewed in Klein et al., 2000; Grant and Cahn, 2005; Di Marzo,
2008). There is accumulating evidence to suggest that endo-
cannabinoids and their receptors play important roles in bone
metabolism by regulating bone mass, bone loss, and bone cell
function. This review summarizes in vitro and in vivo ﬁndings
relating to the action of cannabinoid ligands in the skeleton.
THE SKELETAL ENDOCANNABINOID SYSTEM
CANNABINOID RECEPTOR LIGANDS IN BONE
Cannabinoid receptor ligands can be classiﬁed into three groups
based on their source of production; endogenous cannabi-
noids (endocannabinoids), phytocannabinoids, and synthetic
cannabinoids. Two of the best characterized endocannabi-
noids are N-arachidonoylethanolamine (anandamide) and 2-
arachidonoylglycerol (2-AG). The endocannabinoids anandamide
and 2-AG are responsible for most pharmacological actions asso-
ciated with cannabinoid receptors in mammalian cells (Reviewed
in Pertwee, 2005). Anandamide and 2-AG are both deriva-
tives of arachidonic acid and are produced from breakdown
of glycerophospholipids in the cell membrane. Anandamide
is synthesized from N-arachidonoyl phosphatidylethanolamine
(NAPE) by the enzyme NAPE-phospholipase D (NAPE-PLD),
whereas synthesis of 2-AG occurs through the action of phos-
pholipase C (PLC) and the diacylglycerol lipases alpha and beta
(DAGLα and DAGLβ) on membrane phospholipids (Di Marzo
et al., 1996; Maejima et al., 2001a,b; Simon and Cravatt, 2006).
Once formed, endocannabinoids are transported across cell mem-
branes by passive diffusion or endocytosis (for extensive review,
refer to Fowler, 2012; Hermann et al., 2006). Anandamide and
2-AG are highly expressed in the brain and are also detected
in a number of peripheral tissues including heart, liver, kid-
ney, testis, and blood (Felder et al., 1993, 1996; Stella et al.,
1997; Kondo et al., 1998; Di Marzo et al., 2002; Ross, 2003; van
der Stelt and Di Marzo, 2005; Tam et al., 2008). Endocannabi-
noids have a short half life due to the fact that they are rapidly
degraded by a variety of enzymes including fatty acid amide hydro-
lase (FAAH) and monoacylglycerol lipase (MGAL; Dinh et al.,
2002). It should be noted, however, that FAAH is not speciﬁc for
cannabinoids and degradesmany other lipid containingmolecules
(Basavarajappa, 2007).
There is evidence that the endocannabinoids 2-AG and anan-
damide are produced endogenously in the bone marrow and
within themetabolically active trabecular compartment (Bab et al.,
2008; Tam et al., 2008). A number of studies have shown that
osteoblasts and osteoclasts are capable of producing anandamide
and 2-AG in culture. Ridge et al. (2007) reported in abstract form
that cultured osteoblast-like cells MC3T3-E1 and mouse osteo-
clasts produced 2-AG in vitro and that anandamide was produced
by cultured osteoblasts but not osteoclasts. A recent study by the
same group reported that the differentiation of human osteo-
clasts from monocytes is associated with a reduction in 2-AG
levels and an increase in anandamide levels (Whyte et al., 2012).
Rossi et al. (2009) reported that cultured human osteoclasts pro-
duced 2-AG and detectable quantities of anandamide; levels of
both cannabinoids increased when the cultures were treated with
the FAAH inhibitor URB597. Taken together, these observations
indicate that 2-AG and anandamide are probably produced locally
within bone and by bone cells in culture. In a study by Richard-
son et al. (2008), neither 2-AG nor anandamide were detected in
synovial ﬂuid from normal subjects, but both endocannabinoids
www.frontiersin.org November 2012 | Volume 3 | Article 136 | 1
“fendo-03-00136” — 2012/11/16 — 13:15 — page 2 — #2
Idris and Ralston Role of cannabinoids in the regulation of bone remodeling
were detected in synovial ﬂuid from patients with osteoarthritis
(OA) and rheumatoid arthritis (RA). Interestingly 2-AG levels in
this study were higher in patients with OA as compared with RA.
Cannabinoid receptors are also activated by plant derived
cannabinoids termed phytocannabinoids. The Cannabis sativa
plant contains a large number of phytocannabinoids such as Δ9-
tetrahydrocannabinol (THC) which is an agonist at CB1 and
CB2 receptors. It should be noted, however, that many phyto-
cannabinoids such as cannabidiol bind weakly to cannabinoid
receptors (reviewed by Mechoulam, 2005). A large number of
synthetic cannabinoids have also been prepared some of which
such as CP55,940, JWH133, and HU308 act as agonists thereby
mimicking the action of endocannabinoids at a number of tar-
gets (Pertwee, 2005). On the other hand, a variety of synthetic
compounds including SR141716A (also known as Rimonabant),
AM251, and AM630 are described as inverse agonists/antagonists
due to their ability to down-regulate the activity of cannabinoid
receptors in the presence and absence of agonist binding (Gatley
et al., 1996, 1997; Bouaboula et al., 1997; Hosohata et al., 1997a,b;
Landsman et al., 1998; Lan et al., 1999; Ross et al., 1999; Meschler
et al., 2000). For a comprehensive list of pharmacological proper-
ties of some of the most important cannabinoid receptor ligands
refer to (Pertwee, 2005, 2010).
CANNABINOID RECEPTORS IN BONE
Endocannabinoids and their synthetic analogs bind to and acti-
vate two known cannabinoid receptors: CB1 andCB2 (Maccarrone
and Finazzi-Agro, 2002; Pertwee and Ross, 2002). Recent stud-
ies suggest that the “orphan” G protein-coupled receptor GPR55
might represent a third cannabinoid receptor (Begg et al., 2005;
Ryberg et al., 2007). The CB1 receptor, encoded by the CNR1
gene was the ﬁrst cannabinoid receptor to be identiﬁed and
it’s mainly expressed in the brain (Matsuda et al., 1990). In the
skeleton, CB1 receptors are expressed on nerve ﬁbers interven-
ing bone (Tam et al., 2006, 2008) and on cells of the immune
system within the BM compartment (Klein et al., 2000, 2003).
We and others reported that CB1 receptors are also present
on osteoblasts, osteoclasts, and BM derived adipocytes at both
protein and mRNA levels (Idris et al., 2009; Rossi et al., 2009).
The CB2 receptor encoded by the CNR2 gene was originally
identiﬁed in macrophages in the marginal zone of the spleen
(Munro et al., 1993) but is now known to be expressed in
many other tissues including bone and synovial joints as well
as some regions of the central nervous system (Bouaboula et al.,
1993; Galiegue et al., 1995; Pertwee, 1997; Nong et al., 2001;
Klein et al., 2003; Idris et al., 2005; Ofek et al., 2006; Scutt and
Williamson, 2007; Palazuelos et al., 2008). CB2 receptors are
also expressed by osteoblasts, osteoclasts, and osteocytes at sig-
niﬁcantly higher level than that reported for CB1 (Idris et al.,
2005; Ofek et al., 2006; Rossi et al., 2009; Whyte et al., 2012).
Recent studies reported that bone cells including osteoblasts
and osteoclasts also express GPR55 which is known to be tar-
geted by endocannabinoids and synthetic cannabinoid ligands
(Smart et al., 2000; Saunders et al., 2007; Abed et al., 2009; Rossi
et al., 2009; Whyte et al., 2009). The GPR55 receptor encoded
by the GRP55 gene is widely expressed but the highest levels
are detected in the adrenals, the gastrointestinal tract, and the
brain (Ryberg et al., 2007). It should be noted that cannabinoids
such as anandamide can bind to other receptors such as nico-
tinic acetylcholine receptors, calcium channels, voltage-gated
potassium channels, and transient receptor potential vanilloid
receptors (TRPVs; Di Marzo et al., 2002; van der et al., 2005),
although the physiological signiﬁcance of this in the skeleton is
unclear.
CANNABINOID RECEPTOR SIGNALING IN BONE
Cannabinoid receptors are a class of cell membrane recep-
tors that belongs to the G protein-coupled receptor superfamily
(Bouaboula et al., 1996; Ross et al., 1999). The CB1 recep-
tor is constitutively active and therefore is able to transduce
a biological signal in the absence of ligand (Carayon et al.,
1998). Accordingly, cannabinoid receptor agonists inhibit adeny-
lyl cyclase causing reduction in intracellular levels of cyclic
adenosine monophosphate (cAMP; Demuth and Molleman,
2006). CB1 and CB2 receptors are also linked to a variety of
other second messengers including nuclear factor of kappa B
(NFκB), p38 mitogen-activated protein kinase (MAPK), extracel-
lular signal-regulated kinases (ERKs), c-Jun N-terminal kinases
(JNKs), PI3/Akt and focal adhesion kinase (FAK) phosphoryla-
tion (Derkinderen et al., 1996; Daaka et al., 1997; Guzman et al.,
2001b; Ho et al., 2002; Molina-Holgado et al., 2002; Sanchez
et al., 2003; Karanian et al., 2005; Demuth and Molleman, 2006).
The CB1 receptor has also been shown to couple to genera-
tion of the lipid second messenger ceramide by sphingomyelin
hydrolysis and through de novo synthesis of ceramide (Guz-
man et al., 2001a). Cannabinoid receptor antagonists/inverse
agonists such as the CB1 selective AM251 and CB2 selective
AM630 block the effects of cannabinoid receptor agonists as
well as down-regulate the constitutive activity of cannabinoid
receptors in the absence of agonist binding (Bouaboula et al.,
1997, 1999). Very little is known about the signaling mech-
anisms used by cannabinoid receptors to inﬂuence bone cell
activity. There is evidence that the CB1 receptor regulates
osteoblast and adipocyte differentiation by modulating intracel-
lular cAMP levels (Idris et al., 2009). Moreover, recent studies
showed that CB2 selective agonists induce mitogenic effects in
osteoblasts via activation of a Gi protein-cyclin D1 and ERK1/2
axis (Ofek et al., 2011; Sophocleous et al., 2011). However,
the mechanisms by which the CB1 and CB2 receptor regulate
osteoclast differentiation and activity have not yet been fully
clariﬁed.
The GPR55 receptor is coupled to the G12 family of proteins
(Gα12 and Gα13) rather than the Gi/o proteins. The signaling
pathways downstream of GPR55 have been less widely studied
than CB1 and CB2 but ligand-induced activation of GPR55 has
been shown to activate the small GTP binding proteins RhoA,
Cdc42, and Rac1 (Ryberg et al., 2007), to trigger activation of
the ERK/MAPK signaling cascade (Kapur et al., 2009); to elicit
release of intracellular calcium through activation of PLC (Lauck-
ner et al., 2008; Kapur et al., 2009) and to activate NFAT through
effects on intracellular calcium (Ross, 2009). Activation of GPR55
with O-1602 and lysophosphatidylinositol (LPI) in osteoclasts has
been reported to increase levels of active GTP-bound Rho and to
stimulate ERK phosphorylation (Whyte et al., 2009).
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REGULATION OF OSTEOCLASTIC BONE RESORPTION BY
CANNABINOIDS
The classical cannabinoid receptors CB1 and CB2 and the orphan
receptor GPR55 all play signiﬁcant roles in the regulation of osteo-
clast function and bone resorption. Idris et al. (2005) were ﬁrst
to report that genetic inactivation of the CB1 receptor results in
high peak bone mass in young mice. In this study, a detailed
micro-computed tomography scanning of bone and histomor-
phometric analysis of bone formation and resorption revealed that
mice deﬁcient in CB1 receptor have less osteoclasts and reduced
bone resorption (Idris et al., 2005). These ﬁndings have led to the
realization that cannabinoid receptors play a signiﬁcant role in
the regulation of peak bone mass. In keeping with these obser-
vations, the CB1 selective antagonist/inverse agonists AM251 and
SR141716A have been reported to cause osteoclast apoptosis and
inhibit osteoclast formation in vitro and osteoclasts cultured from
CB1 deﬁcient mice were found to be resistant to the effects of
AM251 indicating that the mechanism of osteoclast inhibition
was mediated at least in part, by the CB1 receptor (Idris et al.,
2005). Further studies have shown that the CB1 selective antago-
nist/inverse agonist AM251 (1–3mg/kg/day) prevents ovariectomy
induce bone loss in wild type mice and that CB1 deﬁcient mice
are resistant to ovariectomy-induced bone loss, ﬁndings which
support the view that activation of the CB1 receptor promotes
osteoclast differentiation and bone resorption (Idris et al., 2005).
There is evidence that the defect in osteoclast formation in CB1
deﬁcient mice is caused both, by a reduction in the sensitivity of
osteoclast precursors to RANKL and a reduction in the ability of
CB1 deﬁcient osteoblasts to support osteoclast formation due to
reduced RANKL expression (Idris et al., 2009).
The CB2 receptor also regulates osteoclast activity and bone
resorption, but research in this area to date has yielded rather con-
tradictory results. Ofek et al. (2006) reported that CB2 deﬁcient
mice developed osteoporosis with increasing age due to increased
bone turnover. In keeping with these ﬁndings it was reported in
the same study that the CB2 selective agonist HU308 inhibited
RANKL-induced osteoclast formation in bone marrow and RAW
264.7 cultures in vitro. In complete contrast to these ﬁndings,
Idris and colleagues reported, that anandamide and 2-AG,HU308
and JWH133 enhanced M-CSF- and RANKL-induced osteoclast
formation over the concentration range 1–1000 nM (Idris et al.,
2005),whereas theCB2 selective antagonist/inverse agonistAM630
was inhibitory (Idris et al., 2005, 2008). Further studies by Idris
et al. (2008) showed that bone marrow cells isolated from CB2
deﬁcient mice produce fewer osteoclasts in response to RANKL
than wild type controls and that CB2 deﬁcient mice were partially
protected from ovariectomy-induced bone loss as compared with
wild type littermates. In agreement with these observations others
have reported that the endocannabinoids 2-AG and anandamide
were found to stimulate bone resorption by human osteoclasts
in vitro (Ridge et al., 2007; Whyte et al., 2012). Schuehly et al.
(2011) have recently introduced a new class of highly CB2 selective
ligands that strongly inhibited RANKL stimulated osteoclasto-
genesis in murine and human cultures. In the same study, the
authors went to demonstrate that endocannabinoids stimulate
osteoclast formation and these effects were signiﬁcantly inhib-
ited by natural biphenyl neolignan derivatives (Schuehly et al.,
2011). In vivo, Idris et al. (2008) showed that the CB2 selective
antagonist/inverse agonist AM630 prevents from ovariectomy-
induced bone loss in a CB2 dependent and independent manner
depending on administered dose. In broad agreement with this,
Geng et al. (2010) showed that AM630 protected against the
development of titanium particle induced osteolytic bone loss
by reducing osteoclastogenesis. Furthermore, Lunn et al. (2007)
reported that the novel CB2 selective antagonist Sch.036 pre-
vented bone damage in arthritic mice. Taken together these
studies indicate that pharmacological inhibition of the CB2 recep-
tor inhibits osteoclast formation and reduces bone loss in adult
mice. However, Rossi et al. (2009) reported that the CB2 selective
antagonist/inverse agonistAM630 at high concentrations (10μM)
stimulated human osteoclast formation. The stimulatory effects
of AM630 on osteoclast formation in human cultures reported by
Rossi and colleagues are exactly opposite to the inhibitory effects
if AM630 on osteoclast formation in mouse cultures reported
by Idris et al. (2005, 2008). The reasons for this are unclear
but possibilities include; species differences in responsiveness to
AM630, off-target effects of AM630 at the high concentrations
that were used or factors such as the choice of serum, some of
which contain bioactive amounts of the endocannabinoid 2-AG
sufﬁcient to inﬂuence osteoclast differentiation and activity
(Marazzi et al., 2011).
Recent studies have shown that the GPR55 receptor regulates
osteoclast activity and bone resorption. A study by Whyte et al.
(2009) showed that the GPR55 agonists L-α-LPI and O-1602 both
inhibited osteoclast formation from bone marrow macrophages
in vitro, whereas the GPR55 antagonist cannabidiol increased
osteoclast formation. Although GPR55 agonists were found in
this study to inhibit osteoclast formation, they actually stimu-
lated the resorptive activity of osteoclasts. Conversely, the GPR55
antagonist cannabidiol enhanced osteoclast formation and inhib-
ited resorptive activity. In keeping with these observations male
mice with targeted inactivation of GPR55 were found to have
increased numbers of osteoclasts in vivo, but these appeared
unable to resorb bone effectively since trabecular bone mass was
increased and cartilage remnants at the growth plate were not
resorbed efﬁciently. Rather surprisingly, female mice deﬁcient in
GPR55 were found to have reduced numbers of osteoclasts and
increased amounts of unresorbed growth plate cartilage, but had
normal bone mass (Whyte et al., 2009). Further studies in wild
type mice revealed that cannabidiol reduced levels of CTX – a
biochemical marker of bone resorption – consistent with the in
vitro observations. Taken together these observations indicate that
activation of GPR55 inhibits osteoclast formation, but increases
the ability of osteoclasts to resorb bone. Conversely, inhibition
of GPR55 appears to increase osteoclast formation but reduces
the ability of osteoclasts to resorb bone. The cannabinoid deriva-
tive ajulemic acid (AJA) which is structurally similar to both CBD
and THC has been found to inhibit formation of multinucleated
TRAP positive cells in RANKL treated RAW264.7 cultures and in
M-CSF and RANKL treated bone marrow macrophages (George
et al., 2008). The mechanism by which AJA regulates osteoclast
formation is unclear since it has weak afﬁnity for CB2, and pre-
sumably does not activate CB1 in view of the fact that it lacks
psychotropic properties. Possibilities would include an effect on
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PPARγ, which has recently been implicated in the regulation of
osteoclast differentiation (Wan et al., 2007) or an effect on the
GPR55 receptor.
In summary, there is evidence that both cannabinoid“classical”
receptors CB1 and CB2 and the “orphan” receptor GPR55 reg-
ulate osteoclast activity and bone resorption. Conﬂicting results
have been reported with regard to the role of CB2 in regulating
osteoclast differentiation in vitro with stimulatory effects reported
by some workers and inhibitory effects by others. The reasons
for these differences remain unclear at present but one expla-
nation may be the fact that many cannabinoid receptor ligands
have complex pharmacology and are not entirely speciﬁc for the
cannabinoid receptors they were originally designed to target. For
example, AM251, which was classically considered to be spe-
ciﬁc CB1 selective antagonist/inverse agonist has recently been
reported to act as a GPR55 agonist (Lauckner et al., 2008; Ross,
2009). Perplexingly SR141716A has been reported to act as a
GPR55 antagonist (Kapur et al., 2009) or agonist (Lauckner et al.,
2008), depending on the assay system used. Similarly, the syn-
thetic cannabinoid agonist CP55,940 has been shown to be act as
a GPR55 agonist/partial agonist and JWH015, formerly consid-
ered a speciﬁc CB2 agonist has been shown to be a GPR55 agonist
(Kapur et al., 2009). These data indicate that the interpretation
of some ligand activities previously attributed to effects on the
CB1 or CB2 receptors may have been confounded by effects on
the GPR55 receptor. Further research will clearly be required to
investigate these issues and to explore the relative roles that CB1,
CB2, and GPR55 play in regulating osteoclast differentiation and
function.
REGULATION OF OSTEOBLAST FUNCTION AND BONE
FORMATION BY CANNABINOIDS
Endocannabinoids and their receptors are involved in the reg-
ulation of osteoblast differentiation and bone formation. Mice
with targeted deletion of the CB1 receptor have been found to
develop osteoporosis with increasing age due to reduced bone
formation and accumulation of adipocytes in the bone marrow
space (Idris et al., 2009). In these studies, bone marrow stro-
mal cells from CB1 deﬁcient mice had an increased capacity for
adipocyte differentiation and a reduced capacity for osteoblast
differentiation and these effects were reproduced by treatment of
wild type cultures with the CB1 selective antagonist/inverse ago-
nist AM251 (Idris et al., 2009). Furthermore, the CB1 selective
antagonist/inverse agonist AM251 was found to block the stimu-
latory effect of CP55,490 on bone nodule formation in vitro (Idris
et al., 2009). Signaling studies have shown that blockade of CB1
receptors with AM251 in osteoblast like cells and preadipocytes
up-regulated cAMP, stimulated CREB phosphorylation, inhibited
expression of the osteoblast-speciﬁc transcription factor RUNX2
and increased expression of the adipocyte-speciﬁc transcription
factor PPARγ (Idris et al., 2009). Other research has shown that
the CB1 receptor plays a key role in regulating the increased
bone formation that accompanies traumatic brain injury (TBI).
This was investigated by Tam et al. (2008) who reported that the
expected increase in bone formation following TBI was absent in
CB1 deﬁcient mice, but was present in wild type and CB2 deﬁ-
cient mice. In this study, Tam et al. (2008) also reported that
TBI induced bone formation in wild type mice was abolished
by the beta adrenergic receptor agonist isoproterenol. This led
the authors to speculate that CB1 receptors present on presy-
naptic nerve endings in bone might enhance bone formation by
suppressing catecholamine release (Tam et al., 2008). Although
this is a plausible hypothesis, the experiments conducted did not
determine whether the effect of the CB1 receptor on bone for-
mation was truly mediated by this sequence of events or not.
Other studies by the same authors (Tam et al., 2006) showed that
bone formation rate and mineral apposition rate were reduced
in young (9–12-week old) CB1 deﬁcient mice on a CD1 back-
ground, again conﬁrming that CB1 appears to play a key role in
regulating bone formation. Recent ﬁndings have shown that the
CB1 receptor plays a role in glucocorticoid-induced bone loss (Wu
et al., 2011; Ko et al., 2012). CB1 blockage attenuated the deleteri-
ous actions of glucocorticoid treatment on osteoblast activity and
bone formation, signiﬁcantly reduced bone loss and abrogated
marrow adiposity (Wu et al., 2011; Ko et al., 2012). Mechanistic
studies revealed that CB1 regulates glucocorticoid-induced dys-
function in osteoblasts via activation of a number of pathways
including PI3/Akt, MAPK and runt-related transcription factor 2
and peroxisome proliferator-activated receptor 2 (Wu et al., 2011;
Ko et al., 2012).
The CB2 receptor also plays a role in regulating bone forma-
tion. The CB2 selective agonists HU308, JWH133, and JWH015
have all been shown to stimulate bone nodule formation in bone
marrow stromal cell cultures in vitro, although similar effects have
been observed with non-selective agonists including anandamide,
2-AG, CP55,940, and WIN 55,212 (Ofek et al., 2006; Scutt and
Williamson, 2007; Idris et al., 2009). A speciﬁc role for CB2 recep-
tors in mediating these effects is supported by the fact that bone
marrow stromal cells from CB2 deﬁcient mice have a reduced
capacity to differentiate into bone nodules when compared with
those of wild type littermates. Although mice with targeted inac-
tivation of CB2 have increased bone turnover, there is a relative
defect in bone formation as evidenced by the fact that CB2 deﬁ-
cient mice develop age-related osteoporosis (Ofek et al., 2006).
This is consistent with a model whereby CB2 is required for
maintenance of normal bone formation in high bone turnover
states.
The role of theGPR55 receptor on bone formation has not been
extensively studied, but Whyte et al. (2009) found no signiﬁcant
abnormalities in histomorphometric indices of bone formation in
GPR55 knockout mice and also reported that the GPR55 agonist
O-1602had little effect onbonenodule formation inmouse calvar-
ial osteoblast cultures. In view of this it seems unlikely that GPR55
plays a major role in regulating bone formation. Several phyto-
cannabinoids including cannabidiol, cannabinol, cannabidivarin,
THC, and tetrahydrocannabivarin (THCV) have been reported
to stimulate bone nodule formation, collagen production, and
alkaline phosphatase activity in cultures of bone marrow stromal
cells (Scutt and Williamson, 2007). At the present time, however,
it is unclear to what extent these compounds are acting through
cannabinoid receptors or othermolecular targets. For example the
phytocannabinoid THCV which was found in the above study to
promote bone nodule formation is known to act as an antagonist
of CB1 andCB2 receptors,whichwould be expected to reduce bone
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formation, according to the studies that have been performed in
genetically modiﬁed mice (Ofek et al., 2006; Tam et al., 2006; Idris
et al., 2009). In view of this it is clear that further research will
be required to fully investigate the mechanisms by which these
phytocannabinoids regulate bone cell activity.
In summary, current evidence suggests that both the CB1 and
CB2 receptors play signiﬁcant roles in regulating osteoblast dif-
ferentiation and bone formation in response to TBI and ageing.
The fact that CB1 knockout mice develop accumulation of mar-
row fat also suggests that the CB1 receptor regulates the age-related
“switch” in differentiation potential of bone marrow stromal cells
(Gimble et al., 2006).
REGULATION OF BONE MASS BY CANNABINOID RECEPTORS
A number of genetic and pharmacological studies have reported
that cannabinoid receptors regulate bone mass in health and dis-
ease. Mice with deletion of the CB1, CB2, and GPR55 receptors
all exhibit abnormalities of bone mass although this is depen-
dent to an extent, on background strain, gender and age. The ﬁrst
report of an abnormality in bone mass in relation to the endo-
cannabinoid system came from the studies of Idris and colleagues
who reported that female CB1 deﬁcient mice on inbred (ABH)
and outbred (CD1) backgrounds exhibited high peak bone mass
affecting the trabecular compartment of bone (Idris et al., 2005).
This was found to be due to a defect in osteoclastic bone resorp-
tion and in keeping with this, CB1 deﬁcient mice were found to
be resistant to ovariectomy induced bone loss (Idris et al., 2005).
In a subsequent study, Idris et al. (2009) demonstrated that the
high peak bone mass in CB1 deﬁcient mice was found in both
genders, and went on to show that CB1 deﬁcient mice developed
marked trabecular osteoporosis with increasing age due to a defect
in bone formation and accumulation of marrow fat. Remarkably,
this age-related bone loss occurred despite the fact that osteoclas-
tic bone resorption remained lower in CB1 deﬁcient mice than
in wild type littermates throughout life. In another study Tam
et al. (2006) conﬁrmed that CB1 deﬁcient mice on a CD1 back-
ground had high peak bone mass. Although this was observed
in both genders, the difference was signiﬁcant only for male
mice. In stark contrast to these ﬁndings, CB1 deﬁcient mice on
a C57BL/6 background were found by Tam et al. (2006) to have
reduced peak bone mass when compared with wild type litter-
mates. The molecular mechanisms for these differences remain to
be fully explored but they are probably related to polymorphisms
or mutations in genes that interact with cannabinoid receptors
to regulate cellular responses in different mouse strains. Abnor-
malities of bone mass have also been described in CB2 deﬁcient
mice. The ﬁrst report came from Ofek et al. (2006) who found no
major abnormalities of bone mass in young (8-week old) mice,
but found that by 51 weeks of age, the CB2 deﬁcient mice had
developed marked trabecular osteoporosis with cortical expan-
sion. Histomorphometric examination showed evidence of high
bone turnover indicating that the likely mechanisms of bone loss
was relative uncoupling of bone resorption and bone formation
(Ofek et al., 2006). Idris et al. (2008) also found that peak bone
mass was relatively normal in CB2 deﬁcient mice and recent
studies have shown these mice develop age-related osteoporosis
(Sophocleous et al., 2011).
In a recent study, Sophocleous et al. (2012) have reported in
an abstract form that combined deﬁciency of the CB1 and CB2
receptors enhances peak bone mass but increases age-related bone
loss. At 3 months of age, female CD1 mice deﬁcient in both
CB1 and CB2 receptors had signiﬁcantly higher peak bone mass
than wild type controls due to a signiﬁcant decrease in osteoclast
number and activity. Interestingly, these differences in peak bone
mass and bone resorption observed were quantitatively similar
to those previously observed in single knockouts of CB1 (Idris
et al., 2005, 2009) and CB2 (Sophocleous et al., 2012) in the same
background. By 12 months of age female deﬁcient in both CB1
and CB2 receptors had signiﬁcantly lower trabecular bone mass
and histomorphometric analysis showed that this was associated
with a dramatic increase in bone marrow fat accumulation and a
reduction in osteoblast numbers and bone formation rate com-
pared to wild type controls of similar age. The differences in
bone mass and bone cell activity that the authors observed in
female deﬁcient in both CB1 and CB2 receptors were quantita-
tively similar to those previously observed in single knockouts
of CB1 but not CB2 (Idris et al., 2009). Altogether, these data
indicate that combined CB1 and CB2 deﬁciency enhances peak
bone mass by an effect on bone resorption but predisposes to age-
related osteoporosis by promoting adipocyte differentiation at the
expense of osteoblast differentiation in the bonemarrow compart-
ment. This study demonstrates that CB1 andCB2 have overlapping
but distinctive roles in skeletal homeostasis and show that CB1 in
particular plays a key role in regulating osteoblast and adipocyte
differentiation in the bone marrow compartment. Mice with tar-
geted inactivation of the GPR55 receptor have been reported to
have high peak bone mass affecting the trabecular compartment
of the tibia and femur, but interestingly this was only noted inmale
mice (Whyte et al., 2009). The mechanism seemed to be impair-
ment of bone resorption; although the reasons responsible for the
gender difference in skeletal phenotype in these animals remains
unclear at present.
FUTURE RESEARCH DIRECTIONS
There is a steadily growing body of evidence suggesting that the
skeletal endocannabinoid systemplays a signiﬁcant role in regulat-
ing bone mass and bone turnover. Several outstanding questions
remain unanswered however. One is to deﬁne the mechanisms
by which endocannabinoid production in bone is regulated and
speciﬁcally to determine if it is inﬂuenced by classical calcium
regulating hormones, cytokines and mechanical loading. Further
research is also required to fully deﬁne the signaling pathways
used by these receptors to regulate bone cell activity. There is
evidence to suggest that the CB1 receptor regulates osteoblast
and adipocyte differentiation through a cAMP-mediated pathway
but little is known about the mechanisms by which cannabinoids
regulate osteoclast activity. There have been major discrepancies
between different studies with regard to the effects of differ-
ent cannabinoid receptor ligands on osteoclast differentiation
and function. These remain to be completely resolved but some
of the discrepancies between studies could be due to the fact
that many cannabinoid receptor ligands which were previously
thought to be speciﬁc for CB1 and/or CB2 have now been
shown to have effects on GPR55 signaling (Kapur et al., 2009;
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Pertwee, 2009; Ross, 2009). A further area of research which
remains to be explored is to determine to what extent the CB1
receptor exerts its effects on the skeleton by a central (neu-
ronal) or peripheral mechanism. This is clinically relevant since
if the peripheral effects were predominant, it may be possible
to develop agonists of CB1 that do not cross the blood brain
barrier that could favorably inﬂuence bone formation without
causing adverse psychotropic effects. The outcome of these studies
will greatly enhance our understanding of the role of the skele-
tal endocannabinoid system in bone remodeling and encourage
the development of new treatments for bone diseases based on
targeting cannabinoid receptors.
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